Article information
Full text is only aviable in PDF
References
[1.]
Sociedad Española de Trasplante Hepático. Gastroenterol Hepatol. 2008;31:82–91.
[2.]
P.S. Kamath, R.H. Wiesner, M. Malinchoc, W. Kremers, T.M. Therneau, C.L. Kosberg, et al.
A model to predict survival in patients with end-stage liver disease.
Hepatology, 33 (2001), pp. 464-470
[3.]
L. Forman, M. Lucey.
Predicting the prognosis of chronic liver disease: An evolution from child to MELD.
Hepatology, 33 (2001), pp. 473-475
[4.]
A. Said, J. Williams, J. Holden, P. Remington, R. Gangnon, A. Musat, et al.
Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.
J Hepatol, 40 (2004), pp. 897-903
[5.]
A. Cárdenas, P. Gines.
Predicting mortality in cirrhosis-serum sodium.
N Engl J Med, 359 (2008), pp. 1060-1062
[6.]
W.R. Kim, S.W. Biggins, W.K. Kremers, R.H. Wiesner, P.S. Kamath, J.T. Benson, et al.
Hyponatremia and mortality among patients on the liver-transplant waiting list.
N Engl J Med, 359 (2008), pp. 1018-1026
[7.]
R.M. Merion, D.E. Schaubel, D.M. Dykstra, R. Freeman, F.K. Port, R.A. Wolfe.
The survival benefit of liver transplantation.
Am J Transplant, 5 (2005), pp. 307-313
[8.]
M.R. Lucey, D.E. Schaubel, M.K. Guidinger, S. Tome, R.M. Merion.
A disease specific analysis of the effect of alcoholic liver disease and hepatitis C infection on waiting list mortality, posttransplant mortality and transplant survival benefit.
Am J Transplant, 8 (2008), pp. 196
[9.]
T. Poynard, P. Barthelemy, S. Fratte, K. Boudjema, M. Doffoel, C. Vanemmens, et al.
Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls.
Lancet, 344 (1994), pp. 502-507
[10.]
T. Poynard, S. Naveau, M. Doffoel, K. Boudjema, C. Vanlemmens, G. Mantion, et al.
Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival Multi-centre group.
J Hepatol, 30 (1999), pp. 1130-1137
[11.]
J.F. Trotter, M.J. Osgood.
MELD scores of liver trans- plant recipients according to size of waiting list: Impact of organ allocation and patient outcomes.
JAMA, 291 (2004), pp. 1871-1874
[12.]
R.B. Freeman, R.G. Gish, A. Harper, G.L. Davis, J. Vierling, L. Lieblein, et al.
Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.
Liver Transpl, 12 (2006), pp. S128-S136
[13.]
A. Forner, C. Ayuso, M. Isabel Real, J. Sastre, R. Robles, B. Sangro, et al.
Diagnosis and treatment of hepatocellular carcinoma.
Med Clin (Barc), 132 (2009), pp. 272-287
[14.]
C. Alessandria, O. Ozdogan, M. Guevara, T. Restuccia, W. Jiménez, V. Arroyo, et al.
MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation.
Hepatology, 41 (2005), pp. 1282-1289
[15.]
M.B. Fallon, D.C. Mulligan, R.G. Gish, M.J. Krowka.
Model for End-Stage Liver Disease (MELD) exception for hepatopulmonary syndrome.
Liver Transpl, 12 (2006), pp. S105-S107
[16.]
M.J. Krowka, M.B. Fallon, D.C. Mulligan, R.G. Gish.
Model for End-Stage Liver Disease (MELD) exception for portopulmonary hypertension.
Liver Transpl, 12 (2006), pp. S114-S116
[17.]
M.A. Ramsay.
Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation.
Liver Transpl, 6 (2000), pp. 451-452
[18.]
G.J. Gores, R.G. Gish, R. Shrestha, R.H. Wiesner.
Model for End-Stage Liver Disease (MELD) exception for bacterial cholangitis.
Liver Transpl, 12 (2006), pp. S91-S92
[19.]
S. Horslen, R.G. Gish, R. McDonald.
Model for End-Stage Liver Disease (MELD) exception for primary hyperoxaluria.
Liver Transpl, 12 (2006), pp. S117-S118
[20.]
S. Horslen, S. Sweet, R.G. Gish, R. Shepherd.
Model for End-Stage Liver Disease (MELD) exception for cystic fibrosis.
Liver Transpl, 12 (2006), pp. S98-S99
[21.]
J. Punch, R.G. Gish.
Model for End-Stage Liver Disease (MELD) exception for uncommon hepatic tumors.
Liver Transpl, 12 (2006), pp. S122-S123
[22.]
E. Pomfret, R.G. Gish, D. Brandhagen.
Model for End-Stage Liver Disease (MELD) exception for familial amyloidotic polyneuropathy.
Liver Transpl, 12 (2006), pp. S100-S101
[23.]
P. Sheiner, J. Belghiti, R.G. Gish, C. Miller.
Model for End-Stage Liver Disease (MELD) exception for small-for-size syndrome.
Liver Transpl, 12 (2006), pp. S120-S121
[24.]
L. Arrazola, D. Moonka, R.G. Gish, G.T. Everson.
Model for End-Stage Liver Disease (MELD) exception for polycystic liver disease.
Liver Transpl, 12 (2006), pp. S110-S111
[25.]
G.J. Gores, R.G. Gish, D. Sudan, C.B. Rosen.
Model for End-Stage Liver Disease (MELD) exception for cholangocarcinoma or biliary dyspepsia.
Liver Transpl, 12 (2006), pp. S95-S97
[26.]
W.K. Washburn, R.G. Gish, P.S. Kamath.
Model for End-Stage Liver Disease (MELD) exception for Budd-Chiari syndrome.
Liver Transpl, 12 (2006), pp. S93-S94
[27.]
J. Ham, R.G. Gish, K. Mullen.
Model for End-Stage Liver Disease (MELD) exception for hepatic encephalopathy.
Liver Transpl, 12 (2006), pp. S102-S104
[28.]
P. Sheiner, R.G. Gish, A. Sanyal.
Model for End-Stage Liver Disease (MELD) exception for portal hypertensive GI bleeding.
Liver Transpl, 12 (2006), pp. S112-S113
[29.]
W.K. Washburn, R.G. Gish.
Model for End-Stage Liver Disease (MELD) exception for severe pruritis.
Liver Transpl, 12 (2006), pp. S119
[30.]
H.R. Rosen, M. Prieto, T. Casanovas-Taltavull, V. Cuervas-Mons, O. Guckelberger, P. Muiesan, et al.
Validation and refinement of survival models for liver retransplantation.
Hepatology, 38 (2003), pp. 460-469
[31.]
J.D. Eason, T.A. Gonwa, C.L. Davis, R.S. Sung, D. Gerber, R.D. Bloom.
Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK).
Am J Transplant, 8 (2008), pp. 2243-2251
[32.]
D.E. Schaubel, C.S. Sima, N.P. Goodrich, S. Feng, R.M. Merion.
The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality.
Am J Transplant, 8 (2008), pp. 419-425
[33.]
S.V. McDiarmid, R.M. Merion, D.M. Dykstra, A.M. Harper.
Use of a pediatric end-stage liver disease score for deceased donor allocation: The United States experience.
Indian J Pediatr, 74 (2007), pp. 387-392
[34.]
C. Bourdeaux, T. Thanh Tri, J. Gras, E. Sokal, J.B. Otte, J. De Ville de Goyet, et al.
PELD Score and posttransplant outcome in pediatric liver transplantation: A retrospective study of 100 recipients.
Transplantation, 79 (2005), pp. 1273-1276
[35.]
S.V. McDiarmid, R. Anand, A.S. Lindblad, the Principal Investigators and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group.
Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation.
Transplantation, 74 (2002), pp. 173-181
[36.]
G.V. Mazariegos, R. Anand, S.V. McDiarmid.
Validation of PELD Severity Score in a Pediatric Transplant Candidate Database.
Am J Trans, 2 (2002), pp. 251
[37.]
S.V. McDiarmid, N.P. Goodrich, A.M. Harper, R.M. Merion.
Liver transplantation for Status 1: The consequences of good intentions.
Liver Transpl, 13 (2007), pp. 699-707
Publish in
Cirugía Española
Special content about COVID-19
- With COVID-19 came the change and expansion of MAS programs in breast pathology
- Impact of COVID-19 pandemic in thoracic surgery training in Spain
- Crossing borders to change lives: Surgical mission amidst the COVID-19 pandemic
- Evolutionary analysis of patient’s morbidity and mortality in emergency surgical care during the pandemic: Retrospective comparison between first and second waves of COVID-19
Cirugía Española (English Edition) follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals